A Novel Approach to Assess the Potency of Topical Corticosteroids.

Emax model active pharmaceutical ingredients chromameter potency skin blanching response topical corticosteroids vasoconstrictor assay

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
13 Sep 2021
Historique:
received: 02 07 2021
revised: 11 08 2021
accepted: 26 08 2021
entrez: 28 9 2021
pubmed: 29 9 2021
medline: 29 9 2021
Statut: epublish

Résumé

The potencies of topical corticosteroid products have mainly been classified using clinical data but in some instances, the US Food and Drug Administration's (FDA's) vasoconstrictor assay (VCA) to assess the skin blanching response has also been used. However, the reported skin blanching response data were often based on a single visual reading and lack information on the dose (amount/quantity) or dose duration. Although several lists classifying potencies of various topical corticosteroid products have been published, the inherent potencies of topical corticosteroid raw materials used as active pharmaceutical ingredients (APIs) have not been investigated. The objective was to rank the inherent potencies of topical corticosteroid APIs and to standardize dosing such that the relevant compounds could be compared on a normalized molar basis. The potencies of clobetasol propionate, halcinonide, mometasone furoate, and fluocinolone acetonide were compared using the resulting

Identifiants

pubmed: 34575532
pii: pharmaceutics13091456
doi: 10.3390/pharmaceutics13091456
pmc: PMC8466269
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Biopharmaceutics Research Institute, Rhodes University, Grahamstown, South Africa
ID : BRI Grant No. KZ2/16

Commentaires et corrections

Type : ErratumIn

Références

Health Technol Assess. 2004 Nov;8(47):iii,iv, 1-120
pubmed: 15527669
Arch Dermatol. 1968 Apr;97(4):407-10
pubmed: 4966856
Eur J Pharm Biopharm. 2008 Mar;68(3):453-66
pubmed: 17826047
J Dermatolog Treat. 2006;17(3):133-5
pubmed: 16854751
J Am Acad Dermatol. 1989 May;20(5 Pt 1):791-6
pubmed: 2715430
Clin Pharmacol Ther. 1999 Oct;66(4):346-57
pubmed: 10546918
Drug Intell Clin Pharm. 1988 May;22(5):412-5
pubmed: 3391112
Exp Dermatol. 2015 May;24(5):393-5
pubmed: 25707534
Br J Dermatol. 1985 Oct;113(4):502-3
pubmed: 4063187
J Dermatol. 2006 Oct;33(10):684-91
pubmed: 17040497
Arch Dermatol. 1972 Dec;106(6):825-7
pubmed: 4639246
Pediatr Dermatol. 1996 May-Jun;13(3):239-45
pubmed: 8806127
Arch Dermatol. 1989 Nov;125(11):1509-11
pubmed: 2817915
J Am Acad Dermatol. 2006 Jan;54(1):1-15; quiz 16-8
pubmed: 16384751
J Am Acad Dermatol. 1990 Sep;23(3 Pt 1):458-62
pubmed: 2212144
Nucleic Acids Res. 2021 Jan 8;49(D1):D1388-D1395
pubmed: 33151290
Am Fam Physician. 2009 Jan 15;79(2):135-40
pubmed: 19178066
Arch Dermatol. 1970 May;101(5):531-7
pubmed: 5444076
Arch Dermatol. 1985 Jan;121(1):63-7
pubmed: 3881088
Int J Dermatol. 1992 Oct;31 Suppl 1:38-40
pubmed: 1428467
Clin Pharmacokinet. 1981 Nov-Dec;6(6):429-53
pubmed: 7032803
Br J Dermatol. 1981 Feb;104(2):179-83
pubmed: 7011356
Arch Dermatol. 1964 May;89:741-6
pubmed: 14122107
Br J Dermatol. 1971 Oct;85(4):381-7
pubmed: 5125641

Auteurs

Michael Zvidzayi (M)

Biopharmaceutics Research Institute, Rhodes University, Grahamstown 6139, South Africa.

Seeprarani Rath (S)

Biopharmaceutics Research Institute, Rhodes University, Grahamstown 6139, South Africa.

Charles Bon (C)

Biostudy Solutions LLC, Wilmington, NC 28401, USA.

Sagaran Abboo (S)

Faculty of Pharmacy, Rhodes University, Grahamstown 6139, South Africa.

Isadore Kanfer (I)

Biopharmaceutics Research Institute, Rhodes University, Grahamstown 6139, South Africa.
Leslie Dan College of Pharmacy, University of Toronto, Toronto, ON M5S 3M2, Canada.

Classifications MeSH